Placebo News and Research

RSS

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Antidotes effective for treating acute liver failure patients in early stages of disease

The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.

8 Oct 2009

Triple therapy may benefit patients with chronic obstructive pulmonary disease

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to researchers in Germany.

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Electrostimulation techniques for osteoarthritis still unclear

Despite twenty years of research on the use of electrostimulation techniques (TENS) for treatment of osteoarthritis in the knee, researchers still cannot say whether it reduces pain or physical disability. This is the conclusion of a Cochrane Systematic Review of electrostimulation trials in osteoarthritis

7 Oct 2009

FDA provides Genzyme a complete response letter for Clolar NDA

Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Late-onset sepsis in very low birth-weight newborns may be prevented with supplemental milk protein

Very low birth-weight newborns who received the milk protein lactoferrin alone or in combination with a probiotic had a reduced incidence of late-onset sepsis, according to a study in the October 7 issue of JAMA.

7 Oct 2009

Research must focus on discovering potential causes and treatments for Bell's palsy

Drugs widely prescribed to treat facial paralysis in Bell's palsy are ineffective and are based on false notions of the cause of the condition, according to Cochrane Researchers. They say research must now focus on discovering other potential causes and treatments.

7 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

GNC introduces clinically tested immune defense product

GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.

7 Oct 2009

Brushing removable dentures is better than soaking in enzyme cleaning solutions

Brushing removable dentures with a paste product might be the best way to keep them clean, better than soaking in effervescent or enzyme cleaning solutions, suggests a new review of what little dental literature exists on the topic.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).

7 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

Placebo News and Research

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

New soy germ-based ingredient improves menopausal symptoms

Antidotes effective for treating acute liver failure patients in early stages of disease

Triple therapy may benefit patients with chronic obstructive pulmonary disease

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

FDA approves Daiichi Sankyo's sNDA for Welchol

Electrostimulation techniques for osteoarthritis still unclear

FDA provides Genzyme a complete response letter for Clolar NDA

Opioid drugs may not be effective for osteoarthritis

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Late-onset sepsis in very low birth-weight newborns may be prevented with supplemental milk protein

Research must focus on discovering potential causes and treatments for Bell's palsy

HRT may increase urinary incontinence in postmenopausal women

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

GNC introduces clinically tested immune defense product

Brushing removable dentures is better than soaking in enzyme cleaning solutions

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News